Keryx Biopharma Names Greg Madison EVP And COO

(RTTNews) - Keryx Biopharmaceuticals Inc. (KERX) announced that it has appointed Greg Madison as Executive Vice President and Chief Operating Officer. In this role, Madison will lead the build-out of the commercial organization and related functions to support a potential Zerenex product launch in the United States and internationally.

Madison joins the Company from AMAG Pharmaceuticals (AMAG), where he served as the Executive Vice President and Chief Commercial Officer. Prior to AMAG, Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division.

Madison's prior experience in the Renal division included serving as vice president and general manager of the U.S. business; vice president of U.S. sales; and vice president of U.S. marketing where he led all pre-launch preparation for Renvela, now the leading phosphate binder in the U.S. market.

During his tenure with Genzyme, Madison also had roles in sales management, training, managed markets and reimbursement. Prior to joining Genzyme, Madison spent five years at Jannsen Pharmaceuticals in sales and sales management roles, and began his career in the pharmaceutical industry in sales with Wyeth-Ayerst.